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ADVANCE The ADVANCE study was supported by a grant from the Reynold's Foundation and NHLBI grant 
HL087647. 
AGES Midlife The Age, Gene/Environment Susceptibility Reykjavik Study has been funded by NIH contract 
N01-AG-12100, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart 
Association), and the Althingi (the Icelandic Parliament).  The study is approved by the Icelandic 
National Bioethics Committee, (VSN: 00-063) and the Data Protection Authority.  The 
researchers are indebted to the participants for their willingness to participate in the study. 
Amish We gratefully acknowledge our Amish liaisons, field workers and clinic staff and the extraordinary 
cooperation and support of the Amish community without which these studies would not have 
been possible.  The Amish studies are supported by grants and contracts from the NIH, including 
U01 HL072515, U01 HL84756, the University of Maryland General Clinical Research Center, 
grant M01 RR 16500, the Mid-Atlantic Nutrition and Obesity research Center, grant NIH P30 
DK072488, and by National Research Initiative Competitive Grant no. 2007-35205-17883 from 
the USDA National Institute of Food and Agriculture. We thank our Amish research volunteers for 
their long-standing partnership in research, and the research staff at the Amish Research Clinic 
for their hard work and dedication. 
ARIC The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported 
by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, 
HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, 
HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL087641, 
R01HL59367 and R01HL086694; National Human Genome Research Institute contract 
U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors 
thank the staff and participants of the ARIC study for their important contributions. Infrastructure 
was partly supported by Grant Number UL1RR025005, a component of the National Institutes of 




We acknowledge use of phenotype and genotype data from the British 1958 Birth Cohort DNA 
collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust 
grant 068545/Z/02. (http://www.b58cgene.sgul.ac.uk/). Genotyping for the B58C-WTCCC subset 
was funded by the Wellcome Trust grant 076113/B/04/Z. The B58C-T1DGC genotyping utilized 
resources provided by the Type 1 Diabetes Genetics Consortium, a collaborative clinical study 
sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 
National Institute of Allergy and Infectious Diseases (NIAID), National Human Genome Research 
Institute (NHGRI), National Institute of Child Health and Human Development (NICHD), and 
Juvenile Diabetes Research Foundation International (JDRF) and supported by U01 DK062418. 
B58C-T1DGC GWAS data were deposited by the Diabetes and Inflammation Laboratory, 
Cambridge Institute for Medical Research (CIMR), University of Cambridge, which is funded by 
Juvenile Diabetes Research Foundation International, the Wellcome Trust and the National 
Institute for Health Research Cambridge Biomedical Research Centre; the CIMR is in receipt of a 
Wellcome Trust Strategic Award (079895).  
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BRIGHT The BRIGHT study is supported by the Medical Research Council of Great Britain (G9521010D) 
and the British Heart Foundation (PG/02/128). The BRIGHT study is extremely grateful to all the 
patients who participated in the study and the BRIGHT nursing team.  We also acknowledge the 
contribution of Chris Wallace for the analysis. This work forms part of the research themes 
contributing to the translational research portfolio of Barts and the London Cardiovascular 
Biomedical Research Unit which is supported and funded by the National Institute of Health 
Research. 
CAD_WTCCC  CAD-WTCCC (WTCCC Coronary Artery Disease cases) - Collection of the  CAD-WTCCC cases 
(BHF Family Heart Study) was funded by the British Heart Foundation and the Medical Research 
Council and genotyping by the Wellcome Trust as part of the WTCCC. We thank the members of 
the BHF Family Heart Study Research Group for recruitment. N.J.S. holds a personal chair 
supported by the BHF and also holds a UK NIHR Senior Investigator Award. 
CAPS The CAPS study was supported by grants from the Swedish Research Council, the Swedish 
Cancer Society, and the National Cancer Institute. E.I. was supported by grants from the Swedish 
Research Council, the Swedish Heart - Lung Foundation, the Swedish Society of Medicine, the 
Swedish Foundation for Strategic Research, and the Royal Swedish Academy of Science while 
working with this article. 
CHS This CHS research was supported by NHLBI contracts N01-HC-85239, N01-HC-85079 through 
N01-HC-85086; N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133 
and NHLBI grants HL080295, HL075366, HL087652, HL105756 with additional contribution from 
NINDS. Additional support was provided through AG-023629, AG-15928, AG-20098, and AG-
027058 from the NIA. See also http://www.chs-nhlbi.org/pi.htm. DNA handling and genotyping 
was supported in part by National Center for Research Resources CTSI grant UL 1RR033176, 
National Institute of Diabetes and Digestive and Kidney Diseases grant DK063491 to the 
Southern California Diabetes Endocrinology Research Center. 
COLAUS The CoLaus study received financial contributions from GlaxoSmithKline, the Faculty of Biology 
and Medicine of Lausanne, and the Swiss National Science Foundation (33CSCO-122661). The 
authors thank Vincent Mooser, Dawn Waterworth, Peter Vollenweider and Gérard Waeber, Co-
PIs of the CoLaus study. Special thanks to Murielle Bochud, Yolande Barreau, Mathieu Firmann, 
Vladimir Mayor, Anne-Lise Bastian, Binasa Ramic, Martine Moranville, Martine Baumer, Marcy 
Sagette, Jeanne Ecoffey and Sylvie Mermoud for data collection. JSB is supported by the Centre 
Hospitalier Universitaire Vaudois and the University of Lausanne, Switzerland, the Swiss National 
Science Foundation (grants nb 310000-112552) and the European Union HEALTH-F4-2007-
201550 HYPERGENES grant.  
deCODE We would like to thank participants in deCODE cardiovascular- and obesity studies and 
collaborators for their cooperation. The research performed at deCODE Genetics was part 
funded through the European Community's Seventh Framework Programme (FP7/2007-2013), 
ENGAGE project, grant agreement HEALTH-F4-2007- 201413. 
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DGI The Botnia (DGI) study have been supported by grants from Folkha ̈lsan Research Foundation, 
Sigrid Juselius Foundation, Ministry of Education, Nordic Center of Excellence in Disease 
Genetics, Gyllenberg Foundation, Swedish Cultural Foundation in Finland, Finnish Diabetes 
Research Foundation, Foundation for Life and Health in Finland, Finnish Medical Society, Paavo 
Nurmi Foundation, Perklén Foundation, Ollqvist Foundation, Na ̈rpes Health Care Foundation, the 
Municipal Health Care Center and Hospital in Jakobstad, Health Care Centers in Vasa, Na ̈rpes 
and Korsholm. This work was also partially supported by NIH grant R01-DK075787 to JNH and 
March of Dimes grant 6-FY-09-507 to JNH. 
EGCUT EGCUT received financing by FP7 grants (201413, 245536), also received targeted financing 
from Estonian Government SF0180142s08 and from the European Union through the European 
Regional Development Fund, in the frame of Centre of Excellence in Genomics and Estoinian 
Research Infrastructure’s Roadmap. We acknowledge EGCUT and Estonian Biocentre 
personnel, especially Ms. M. Hass and Mr V. Soo 
EPIC The EPIC Norfolk Study is funded by Cancer Research United Kingdom and the Medical 
Research Council.  
ERF 
(EUROSPAN) 
The genotyping for the ERF study was supported by EUROSPAN (European Special Populations 
Research Network) and the European Commission FP6 STRP grant (018947; LSHG-CT-2006-
01947). The ERF study was further supported by grants from the Netherlands Organisation for 
Scientific Research, Erasmus MC, the Centre for Medical Systems Biology (CMSB) and the 
Netherlands Brain Foundation (HersenStichting Nederland). We are grateful to all patients and 
their relatives, general practitioners and neurologists for their contributions and to P. Veraart for 
her help in genealogy, Jeannette Vergeer for the supervision of the laboratory work and P. 
Snijders for his help in data collection. We would also like to acknowledge Internationale Stichting 
Alzheimer Onderzoek (ISAO) and Hersenstichting Netherlands.  
FamHS The Family Heart Study (FamHS) was supported by NIH grants R01-HL-087700 and R01-HL-
088215 (Michael A. Province, PI) from NHLBI; and R01-DK-8925601 and R01-DK-075681 (Ingrid 
B. Borecki, PI) from NIDDK. 
FENLAND The Fenland Study is funded by the Wellcome Trust and the Medical Research Council, as well 
as by the Support for Science Funding programme and CamStrad. We are grateful to all the 
volunteers for their time and help, and to the General Practitioners and practice staff for help with 
recruitment. We thank the Fenland Study co-ordination team and the Field Epidemiology team of 
the MRC Epidemiology Unit for recruitment and clinical testing. 
FRAM This research was conducted in part using data and resources from the Framingham Heart Study 
of the National Heart Lung and Blood Institute of the National Institutes of Health and Boston 
University School of Medicine.   The analyses reflect intellectual input and resource 
development from the Framingham Heart Study investigators participating in the SNP Health 
Association Resource (SHARe) project. This work was partially supported by the National Heart, 
Lung and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195) and its 
contract with Affymetrix, Inc for genotyping services (Contract No. N02-HL-6-4278). A portion of 
this research utilized the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert 
Dawson Evans Endowment of the Department of Medicine at Boston University School of 
Medicine and Boston Medical Center. 
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FTC Finnish Twin cohort is supported by the European Commission under the programme 'Quality of 
Life and Management of the Living Resources' of 5th Framework Programme (no. QLG2-CT-
2002-01254). S.R was supported by the Academy of Finland Center of Excellence in Complex 
Disease Genetics (213506 and 129680), Academy of Finland (251217), the Finnish foundation 
for Cardiovascular Research and the Sigrid Juselius Foundation. J.K. has been supported by the 
Academy of Finland Centre of Excellence in Complex Disease Genetics. 
Genmets Genmets was supported through funds from The European Community's Seventh Framework 
Programme (FP7/2007-2013), BioSHaRE Consortium, grant agreement 261433. V.S. was 
supported by the Sigrid Juselius Foundation, Finnish Foundation for Cardiovascular research, 
and the Finnish Academy (grant number 129494).  
GERMIFS1 and 
GERMIFS2 
GerMIFS1, GerMIFS2: Supported by the Deutsche Forschungsgemeinschaft and the German 
Federal Ministry of Education and Research (BMBF) in the context of the German National 
Genome Research Network (NGFN-2 and NGFN-plus), the FP6 and FP7 EU funded integrated 
projects Cardiogenics (LSHM-CT-2006-037593), ENGAGE (201413), the bi-national BMBF/ANR 
funded project CARDomics (01KU0908A), and the Nordic Center of Cardiovascular Research 
(NCCR). 
KORA The MONICA/KORA Augsburg studies were financed by the Helmholtz Zentrum München, 
German Research Center for Environmental Health, Neuherberg, Germany, and supported by 
grants from the German Federal Ministry of Education and Research (BMBF). Part of this work 
was financed by the German National Genome Research Network (NGFNPlus, project number 
01GS0834, 01GS0823), software development for sex-specific GWAMAS was partly funded by 
BMBF 01ER1206;	  	  additional funds were from the University of Ulm. Furthermore, the research 
was supported within the Munich Center of Health Sciences (MC Health) as part of LMU 
innovative. 
MICROS For the MICROS study, we thank the primary care practitioners in the villages of the Val Venosta 
and the personnel of the Hospital of Silandro (Department of Laboratory Medicine) for their 
participation and collaboration in the research project. In South Tyrol, the study was supported by 
the Ministry of Health and Department of Educational Assistance, University and Research of the 
Autonomous Province of Bolzano, and the South Tyrolean Sparkasse Foundation. 
Migen The MIGen study was supported by the National Heart, Lung, and Blood Institute's STAMPEED 
genomics research program (R01 HL087676) and the National Center for Research Resources 
(U54 RR020278). This work was also partially supported by NIH grant K23-DK080145 to 
EKS, NIH grant R01-DK075787 to JNH and March of Dimes grant 6-FY-09-507 to JNH. 
NBS-WTCCC We acknowledge use of DNA from The UK Blood Services collection of Common Controls 
(UKBS-CC collection), funded by the Wellcome Trust grant 084183/Z/07/Z and by NIHR 
programme grant to NHSBT (RP-PG-0310-1002).  The collection was established as part of the 
Wellcome Trust Case Control Consortium (WTCCC) 
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120315, 129269, 1114194, Center of Excellence in Complex Disease Genetics and SALVE), 
University Hospital Oulu, Biocenter, University of Oulu, Finland (75617), the European 
Commission (EURO-BLCS, Framework 5 award QLG1-CT-2000-01643), NHLBI grant 
5R01HL087679-02 through the STAMPEED program (1RL1MH083268-01), NIH/NIMH 
(5R01MH63706:02), ENGAGE project and grant agreement HEALTH-F4-2007-201413,  and the 
Medical Research Council, UK (G0500539, G0600705, PrevMetSyn/SALVE).  
The DNA extractions, sample quality controls, biobank up-keeping and aliquotting was performed 
in the National Public Health Institute, Biomedicum Helsinki, Finland and supported financially by 
the Academy of Finland and Biocentrum Helsinki. We thank Professor (emeriti) Paula Rantakallio 
(launch of NFBC1966 and 1986), and Ms Outi Tornwall and Ms Minttu Jussila (DNA biobanking). 
The authors would like to acknowledge the contribution of the late Academian of Science Leena 
Peltonen.  
NHS This study was supported by grants HL71981, CA65725, CA87969, CA49449, CA67262, 
CA50385 and 5UO1CA098233 from the National Institutes of Health. Dr. Lu Qi is a recipient of 
the American Heart Association Scientist Development Award (0730094N) 
NSPHS The Northern Swedish Population Health Study (NSPHS) was funded by the Swedish Medical 
Research Council (project number K2007-66X-20270-01-3), and the Foundation for Strategic 
Research (SSF). The NSPHS as part of EUROSPAN (European Special Populations Research 
Network) was also supported by European Commission FP6 STRP grant number 01947 (LSHG-
CT-2006-01947). This work was also supported by the Swedish Society for Medical Research 
(ÅJ).  The authors are grateful for the contribution of district nurse Svea Hennix for data collection 
and Inger Jonasson for logistics and coordination of the health survey. Finally, the authors thank 
all the community participants for their interest and willingness to contribute to the study. 
NTRNESDA Funding was obtained from the Netherlands Organization for Scientific Research (NWO: 
MagW/ZonMW): Genetic basis of anxiety and depression (904-61-090); Genetics of individual 
differences in smoking initiation and persistence (NWO 985-10-002); Resolving cause and effect 
in the association between exercise and well-being (904-61-193); Twin family database for 
behavior genomics studies (480-04-004); Twin research focusing on behavior (400-05-717); 
Genetic determinants of risk behavior in relation to alcohol use and alcohol use disorder 
(Addiction-31160008); Genotype/phenotype database for behavior genetic and genetic 
epidemiological studies (40-0056-98-9032); Spinozapremie (SPI 56-464-14192); CMSB: Center 
for Medical Systems Biology (NWO Genomics); NBIC/BioAssist/RK/2008.024); BBMRI –NL: 
Biobanking and Biomolecular Resources Research Infrastructure (184.021.007);  the VU 
University: Institute for Health and Care Research (EMGO+ ) and  Neuroscience Campus 
Amsterdam (NCA); the European Science Foundation (ESF): Genomewide analyses of European 
twin and population cohorts (EU/QLRT-2001-01254); European Community's Seventh 
Framework Program (FP7/2007-2013): ENGAGE (HEALTH-F4-2007-201413); the European 
Science Council (ERC) Genetics of Mental Illness (230374); Rutgers University Cell and DNA 
Repository cooperative agreement (NIMH U24 MH068457-06); Collaborative study of the 
genetics of DZ twinning (NIH R01D0042157-01A); the Genetic Association Information Network, 
a public–private partnership between the NIH and Pfizer Inc., Affymetrix Inc. and Abbott 
Laboratories.  
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Society, and the European Union framework program 6 European Special Populations Research 
Network project [contract LSHG-CT-2006-018947]. ORCADES would like to acknowledge the 
invaluable contributions of Lorraine Anderson, the research nurses in Orkney, and the 
administrative team in Edinburgh. DNA extraction for ORCADES was carried out by the Genetics 
Core Laboratory at the Wellcome Trust Clinical Research Facility, WGH, Edinburgh, Scotland 
and SNP genotyping was performed by Helmholtz Zentrum München, GmbH, Neuherberg, 
Germany. 
PLCO The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial was funded by the 
Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National 
Cancer Institute, NIH 
PROCARDIS European Commission (LSHM-CT-2007-037273), the Swedish Heart-Lung Foundation, the 
Swedish Research Council (8691), the Knut and Alice Wallenberg Foundation, the Foundation for 
Strategic Research, the Torsten and Ragnar Söderberg Foundation, the Strategic Cardiovascular 
Programme of Karolinska Institutet and the Stockholm County Council, the Stockholm  County 
Council (560183) and the Wellcome trust core award [090532/Z/09/Z]. MF acknowledges support 
from the British Heart Foundation Centre of Research Excellence, Oxford. 
RS1 The generation and management of GWAS genotype data for the Rotterdam Study is supported 
by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 
911-03-012). This study is funded by the Research Institute for Diseases in the Elderly (014-93-
015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific 
Research (NWO) project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, 
Lizbeth Herrera and Marjolein Peters for their help in creating the GWAS database, and Karol 
Estrada and Maksim V. Struchalin for their support in creation and analysis of imputed data.  
The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, 
Netherlands Organization for the Health Research and Development (ZonMw), the Research 
Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the 
Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality 
of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam 
Study and the participating general practitioners and pharmacists. 
RunMC The RUNMC Nijmegen Biomedical Study was made possible by research investment grants of 
the Radboud University Nijmegen Medical Centre and the Municipality of Nijmegen. 
Sardinia We thank all the volunteers who generously participated in this study, Monsignore Piseddu, 
Bishop of Ogliastra and the mayors and citizens of the Sardinian towns (Lanusei, Ilbono, Arzana, 
and Elini). This work was supported by the Intramural Research Program of the National Institute 
on Aging (NIA), National Institutes of Health (NIH). The SardiNIA (“Progenia”) team was 
supported by Contract NO1-AG-1–2109 from the NIA; the efforts of GRA were supported in part 
by contract 263-MA-410953 from the NIA to the University of Michigan and by research grant 
HG002651 and HL084729 from the NIH (to GRA).  
SASBAC The SASBAC study was supported by funding from the Agency for Science, Technology and 
Research of Singapore (A*STAR), the United States National Institute of Health (NIH) and the 
Susan G. Komen Breast Cancer Foundation. 
SEARCH Paul Pharoah, Douglas Easton, Simon Gayther and the SEARCH and UKOPS teams. SEARCH 
was funded by Cancer Research UK (C490/A10124 and C490/A8339). 
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The study also receives support from the National Institute for Health Research (NIHR) 
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Trust in partnership with King's College London We thank the staff from the TwinsUK, the DNA 
Collections and Genotyping Facilities at the Wellcome Trust Sanger Institute for sample 
preparation; Quality Control of the Twins UK cohort for genotyping (in particular Amy Chaney, 
Radhi Ravindrarajah, Douglas Simpkin, Cliff Hinds, and Thomas Dibling); Paul Martin and Simon 
Potter of the DNA and Genotyping Informatics teams for data handling; Le Centre National de 
Génotypage, France, led by Mark Lathrop, for genotyping; Duke University, North Carolina, USA, 
led by David Goldstein, for genotyping; and the Finnish Institute of Molecular Medicine, Finnish 
Genome Center, University of Helsinki, led by Aarno Palotie. 
VIS The CROATIA-Vis study was funded by grants from the Medical Research Council (UK), 
European Commission Framework 6 project EUROSPAN (Contract No. LSHG-CT-2006-018947) 
and Republic of Croatia Ministry of Science, Education and Sports research grants. (108-
1080315-0302). The funders had no role in study design, data collection and analysis, decision to 
publish, or preparation of the manuscript." 
We would like to acknowledge the staff of several institutions in Croatia that supported the field 
work, including but not limited to The University of Split and Zagreb Medical Schools, Institute for 
Anthropological Research in Zagreb and Croatian Institute for Public Health. The SNP genotyping 
for the CROATIA-Vis cohort was performed in the core genotyping laboratory  of the Wellcome 
Trust Clinical Research Facility at the Western General Hospital, Edinburgh, Scotland, UK. 
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BHS The Busselton Health Study acknowledges the generous support for the 1994/5 follow-up study 
from Healthway, Western Australia and the numerous Busselton community volunteers who 
assisted with data collection and the study participants from the Shire of Busselton. The 
Busselton Health Study is supported by The Great Wine Estates of the Margaret River region of 
Western Australia. The BHS gratefully acknowledges the assistance of the Western Australian 
DNA Bank (NHMRC Enabling Facility) with DNA samples and the support provided by the Ark 
(NHMRC Enabling Facility) for this study. 
COROGENE The study was supported in part by the Aarno Koskelo Foundation, the Finnish Foundation for 
Cardiovascular Research, and the EVO funds of Helsinki University Central Hospital. The 
Corogene study is not supported by industry and all presentations have been carried out in 
academic environment. 
FinGesture FinGesture (Finnish Genetic Study of Arrhythmic Events) - We thank the study participants. We 
also thank Kari Kaikkonen and Marja-Leena Kortelainen for study concept and design, and data 
acquisition and interpretation. The FinGesture cohort is supported by the Juselius Foundation 
(Helsinki, Finland) and the Council of Health of the Academy of Finland (Helsinki, Finland). 
Authors would like to thank Guillaume Lettre, Jean-Claude Tardif, Juhani Juntila, Philipe Goyette 
and Sylvain Foisy for their contributions to the design, implementation and analysis of the GWA 
study of the FinGesture cohort.  In addition, we would like to acknowledge the support of the 
Montreal Heart Institute Foundation.  
GOOD Financial support was received from the Swedish Research Council (K2010-54X-09894-19-3, 
2006-3832 and K2010-52X-20229-05-3), the Swedish Foundation for Strategic Research, the 
ALF/LUA research grant in Gothenburg, the Lundberg Foundation, the Torsten and Ragnar 
Söderberg's Foundation, Petrus and Augusta Hedlunds Foundation, the Västra Götaland 
Foundation, the Göteborg Medical Society, the Novo Nordisk foundation, and the European 
Commission grant HEALTH-F2-2008-201865-GEFOS. We would like to acknowledge Maria 
Nethander at the Genomics core facility at the University of Gothenburg for statistical analyses. 
We would like to thank Dr. Tobias A. Knoch, Luc V. de Zeeuw, Anis Abuseiris, and Rob de Graaf 
as well as their institutions the Erasmus Computing Grid, Rotterdam, The Netherlands, and 
especially the national German MediGRID and Services@MediGRID part of the German D-Grid, 
both funded by the German Bundesministerium fuer Forschung und Technology under grants 
#01 AK 803 A-H and # 01 IG 07015 G for access to their grid resources. We would also like to 
thank Karol Estrada, Department of Internal Medicine, Erasmus MC, Rotterdam, Netherlands for 
advice regarding the grid resources. 
HBCS Helsinki Birth Cohort Study has been supported by grants from the Academy of Finland (Grant 
No. 120386 and 125876 to JGE), the Finnish Diabetes Research Society, Folkhälsan Research 
Foundation, Novo Nordisk Foundation, Finska Läkaresällskapet, the European Science 
Foundation (EuroSTRESS), the Wellcome Trust (Grant No. 89061/Z/09/Z and 089062/Z/09/Z), 
Samfundet Folkhälsan, Finska Läkaresällskapet and the Signe and Ane Gyllenberg foundation. 
We thank all study participants as well as everybody involved in the Helsinki Birth Cohort Study.  
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